Cross-Spectrum Anti-Viral Compounds Needed for Seasonal and Pandemic Infections with Sam Lee Cocrystal Pharma TRANSCRIPT
Download PDFMar 15, 2023
Sam Lee is the Co-CEO and President of Cocrystal Pharma, focused on pandemic viruses and seasonal influenza to develop a drug that is cross-spectrum with a high barrier to drug resistance. Using computational data, as well as high-resolution X-ray data, their platform allows options for newly emerging viruses that also...
Mar 15, 2023
Sam Lee is the Co-CEO and President of Cocrystal Pharma, focused on pandemic viruses and seasonal influenza to develop a drug that is cross-spectrum with a high barrier to drug resistance. Using computational data, as well as high-resolution X-ray data, their platform allows options for newly emerging viruses that also...
Fighting Superbugs with Effective Hypoallergenic Disinfectant and Cleaner with Rayne Guest ArrowClean TRANSCRIPT
Download PDFDec 28, 2022
Rayne Guest, the Founder and CEO of ArrowClean, raises the alarm about the lack of effectiveness of traditional disinfectants to eliminate superbugs and other contaminants. Some of the most vulnerable people are in hospitals where patients and staff are exposed to germs, many of which are not treatable. ArrowClean is...
Dec 28, 2022
Rayne Guest, the Founder and CEO of ArrowClean, raises the alarm about the lack of effectiveness of traditional disinfectants to eliminate superbugs and other contaminants. Some of the most vulnerable people are in hospitals where patients and staff are exposed to germs, many of which are not treatable. ArrowClean is...
Developing Inhibitor Drugs for Use with Antibiotics to Combat Antimicrobial Drug Resistance with Dr. Mike Dudley Qpex Biopharma TRANSCRIPT
Download PDFOct 13, 2021
Dr. Mike Dudley is President and CEO of QpexBiopharma and seeing drug-resistant infections occurring inside the hospital as well as outside the hospital. Qpex is developing IV and oral drugs that are designed to overcome resistance mechanisms in bacteria that render penicillin-like drugs inactive.
Mike explains, "We...